Bayer’s BlueRock Therapeutics establishes European site for cell therapy innovation
Establishment of BlueRock site in Berlin expands company’s footprint and strengthens Bayer’s cell therapy capabilities
09-Jun-2022 -
Bayer AG announced that BlueRock Therapeutics LP (BlueRock), a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, has established a new site for cell therapy innovation on Bayer’s campus in Berlin, Germany. This move comes as part of the company’s focused growth ...
cell therapies
Parkinson's disease